Humanigen Inc (fka HGENQ)

[MWM]

Humanigen Announces Closing of Public Offering of Common Stock
Apr 06, 2021 $HGEN

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that on April 5, 2021 it completed its underwritten public offering of common stock, resulting in gross proceeds to Humanigen of approximately $92.5 million. Humanigen intends to use the net proceeds from the offering for manufacturing and commercial preparation in the event of receipt of an Emergency Use Authorization from the Food and Drug Administration for lenzilumab™ in hospitalized COVID-19 patients, as well as for working capital and other general corporate purposes.